Modifiable Risk Factors Key in Social Inequality of Diabetes

Share this content:
Modifiable Risk Factors Key in Social Inequality of Diabetes
Modifiable Risk Factors Key in Social Inequality of Diabetes

(HealthDay News) -- Modifiable risk factors, particularly health behaviors and body mass index (BMI), measured repeatedly over time, account for about half of the socioeconomic differential observed in type 2 diabetes, according to a study published online Aug. 21 in BMJ.

Silvia Stringhini, Ph.D., of the Lausanne University Hospital in Switzerland, and colleagues conducted a prospective cohort study involving 7,237 adults from the U.K. Civil Service without diabetes, with an average age of 49.4 years, to assess the contribution of modifiable risk factors to social inequalities in type 2 diabetes.

During a mean follow-up of 14.2 years, the researchers identified 818 incident cases of diabetes. Compared with individuals in the highest occupational category, those in the lowest category had a significantly increased risk of developing diabetes (hazard ratio, 1.86). Health behaviors and BMI accounted for 33, 36, and 45 percent, respectively, of this socioeconomic differential when risk factors were assessed at baseline, when they were repeatedly assessed, and when long-term exposure during follow-up was taken into account. A total of 53 percent of the socioeconomic differential was explained with further adjustment for biological risk factors.

"Health behaviors and body mass index explain almost half of the association between socioeconomic status and incidence of type 2 diabetes," the authors write. "Given the increasing burden of type 2 diabetes and the observed increase in social inequalities in prevalence of type 2 diabetes, further efforts to tackle these factors are urgently needed."

Full Text

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs